Zong Kaican, Zhou Hui, Li Wen, Jiang E, Liu Yi, Li Shiying
Department of Respiratory Medicine, the Seventh People's Hospital of Chongqing (Affiliated Central Hospital of Chongqing University of Technology), Chongqing 400054, China.
Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Acta Pharm Sin B. 2023 Nov;13(11):4655-4660. doi: 10.1016/j.apsb.2023.07.007. Epub 2023 Jul 13.
In our retrospective cohort study, we aim to explore whether Azvudine modifies the risk of death in COVID-19 patients. It was conducted on the medical records of patients, consecutively admitted for COVID-19 pneumonia to two hospitals in Chongqing, China. Based on Azvudine treatment exposure, the patients were divided into Azvudine group and non-Azvudine group. We used 1:2 ratio propensity score matching (PSM) in our study to adjust for confounding factors and differences between Azvudine and non-Azvudine groups. There were 1072 patients included in our original cohort. With 1:2 ratio PSM, the Azvudine group included 195 patients and non-Azvudine group included 390 patients. The results showed that Azvudine treatment was associated with improved in-hospital mortality in overall population (OR 0.375, 95% CI 0.225-0.623, 0.001), severe subgroup (OR 0.239, 95% CI 0.107-0.535, = 0.001), critical subgroup (OR 0.091, 95% CI 0.011-0.769, = 0.028) in matched cohort with univariate analysis. And there was a significantly lower in-hospital mortality in overall population (11% 24%, ＜0.001), severe sub-group (10% 32%, 0.001) and critical sub-group (5% 34%, = 0.017) in matched cohort. These results suggest Azvudine can reduce in-hospital mortality in overall COVID-19 patients, severe, and critical subgroup population.
在我们的回顾性队列研究中，我们旨在探讨阿兹夫定是否会改变新冠病毒肺炎患者的死亡风险。该研究基于中国重庆两家医院连续收治的新冠病毒肺炎患者的病历进行。根据是否接受阿兹夫定治疗，将患者分为阿兹夫定组和非阿兹夫定组。我们在研究中采用1:2比例的倾向评分匹配（PSM）来调整混杂因素以及阿兹夫定组和非阿兹夫定组之间的差异。我们的原始队列中有1072名患者。采用1:2比例的PSM后，阿兹夫定组有195名患者，非阿兹夫定组有390名患者。结果显示，在单因素分析的匹配队列中，阿兹夫定治疗与总体人群（OR 0.375，95%CI 0.225 - 0.623，P = 0.001）、重症亚组（OR 0.239，95%CI 0.107 - 0.535，P = 0.001）、危重症亚组（OR 0.091，95%CI 0.011 - 0.769，P = 0.028）的院内死亡率改善相关。并且在匹配队列中，总体人群（11% 对 24%，P＜0.001）、重症亚组（10% 对 32%，P = 0.001）和危重症亚组（5% 对 34%，P = 0.017）的院内死亡率显著更低。这些结果表明，阿兹夫定可降低总体新冠病毒肺炎患者、重症及危重症亚组人群的院内死亡率。
